Hormonal
Semaglutide treatment is associated with a 26% lower risk of fractures compared to sleeve gastrectomy in adults with obesity.
If you are at high risk for fractures (e.g., older age, diabetes, history of falls) and need to lose weight, discuss semaglutide with your provider. This study suggests it may be safer for your bones than sleeve gastrectomy, offering a 26% lower fracture risk in a large real-world cohort. However, because this is observational data, ensure you monitor your bone health and nutrition regardless of the chosen path.
Our results indicate a 26% lower fracture risk for the semaglutide group vs SG, suggesting it may help offset the increased fracture risk typically associated with intentional weight loss.
Why this rating
Retrospective cohort study using real-world EHR data; while large and propensity-matched, it cannot establish causality and has a low E-value indicating susceptibility to unmeasured confounding.
Source
Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy
Jairo A. Noreñ et al. · AACE Endocrinology and Diabetes · 2025
DOI 10.1016/j.aed.2025.10.001
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →